This educational activity explores newer treatments and their role in diabetes therapy, including cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 agonists. The faculty address key issues and provide practice pearls for physicians and pharmacists. The content for this activity is based on questions and comments from participants at a recent educational symposium on this topic.
Learning Objectives
- Review the safety and efficacy of SGLT-2 inhibitors, including recent cardiovascular outcomes trials.
- Compare the various formulations of GLP-1 agonists and their place in type 2 diabetes (T2DM) therapy.
- Discuss the relationship between Non-alcoholic Fatty Liver Disease (NAFLD) and T2DM, including current guidelines.
- Using patient scenarios, apply these concepts to provide interprofessional care to patients with T2DM.
Faculty
Curtis L. Triplitt, Pharm.D., CDCES, FADCES
Clinical Associate Professor, Medicine/Diabetes
University of Texas Health Science Center at San Antonio
Associate Director, Diabetes Research
Texas Diabetes Institute, University Health System
San Antonio, Texas
Eric L. Johnson, M.D.
Associate Professor, Department of Family and Community Medicine
University of North Dakota School of Medicine and Health Sciences
Assistant Medical Director, Altru Diabetes Center
Altru Health System
Grand Forks, North Dakota
Target Audience
This activity was planned to meet the educational needs of physicians, pharmacists, nurse practitioners, and physician assistants caring for patients with type 2 diabetes mellitus.
Format
This activity features slide presentations, active learning, and questions/discussion with faculty. View the system requirements.
Disclosures
In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships.
In this activity, only the individual/s below has disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.
Curtis L. Triplitt
- AstraZeneca; Boehringer Ingelheim; Eli Lilly; Janssen - Speakers Bureau
- Merck - Consultant
Eric L. Johnson
- Medtronic - Speakers Bureau
- Novo Nordisk - Advisory Board, Speakers Bureau
- Sanofi - Advisory Board
Claim CE within 60 Days
Participants should claim CE credit for this home-study activity only if they have not claimed credit for the live activity.
To receive CE credit, complete the steps below within 60 days of completing the activity.
- View entire presentation and answer all polling questions.
- Click "Complete Activity" on the last slide to link to complete the assesment and evaluation.
- Verify credits were successfully transferred to CPE Monitor before the ACPE 60-day deadline by checking your NABP eProfile account.
After the 60-day deadline, ASHP will no longer be able to report credit(s).
CPE Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE #: 0204-0000-19-403-H01-P
Release Date: May 6, 2019
Expiration Date: May 31, 2020
Activity Type: Application-based
CE Credits: 1.0
Activity Fee: Free of charge
CME Information
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.